Towards Healthcare Research & Consulting

North America Latent Tuberculosis Infection Detection Key Players-Business, Deal & Patent Strategies

Date : 30 June 2026

Who are the Market Top Companies and What are Their Offerings?

North America Latent Tuberculosis Infection Detection Market Companies are QIAGEN N.V., ARUP Laboratories, Revvity, Mayo Clinic Laboratories, Danaher Corporation, Laboratory Corporation of America, Sanofi S.A.

What are the Recent Developments in the Market?

  • In February 2025, the Auto-Pure2400 liquid handling platform with the T-SPOT.TB test developed by Revcity, Inc. was announced to have received U.S. FDA approval. This product helps in the accurate diagnosis of latent tuberculosis (TB), supporting timely treatment and containment in the U.S.
  • In October 2025, a dynamic community of healthcare professionals was brought together by Mayo Clinic Center for Tuberculosis (MCCT) at its 2025 TB Clinical Intensive program, which was held for 2 days. The event offered the latest in TB science, public health strategy, and clinical practice.

Market Ecosystem Analysis

Category Key Participants Explanation
Technology Providers QIAGEN, Revvity, Oxford Immunotec (Revvity) Develop interferon-gamma release assay (IGRA) technologies and immunodiagnostic platforms.
Product Manufacturers QIAGEN, Revvity, bioMérieux, BD, Thermo Fisher Scientific Manufacture TB diagnostic kits, laboratory reagents, immunoassay systems and accessories.
Service Providers Labcorp, Quest Diagnostics, Mayo Clinic Laboratories Provide nationwide LTBI testing services using commercial diagnostic platforms.
Platform Providers QIAGEN, BD, bioMérieux, Thermo Fisher Scientific Supply automated laboratory analyzers and diagnostic workflow solutions.
CROs/CDMOs ICON plc, IQVIA Conduct clinical studies and assay validation supporting TB diagnostic development.
Software Vendors Roche Diagnostics Digital Solutions, Thermo Fisher Scientific Informatics Laboratory workflow, LIS integration, diagnostic data management.
Research Institutions CDC, National Institutes of Health (NIH), Johns Hopkins University, University of California San Francisco Conduct TB epidemiology, assay validation and clinical research.
End-User Industries Hospitals, Reference Laboratories, Public Health Departments, Academic Centers, Occupational Health Clinics Primary purchasers and users of LTBI diagnostic solutions.

Market Value Chain Analysis

R&D

  • The R&D of the North America latent tuberculosis infection detection focuses on the development of automated microfluidic IGRAs, host response transcriptomic biomarkers, and point-of-care molecular assays.
  • Key players: QIAGEN N.V., Revvity, and Danaher Corporation.

Clinical Trials and Regulatory Approvals

  • The clinical sensitivity, operational safety, and specificity are evaluated in the clinical trials and regulatory approvals of the latent tuberculosis infection detection in North America.
  • Key players: QIAGEN N.V., Revvity, and Sanofi S.A.

Patient Support and Services

  • Direct employer health navigation programs, automated digital tracking portals, and bilingual community outreach networks are provided in the patient support and services of the latent tuberculosis infection detection in North America.
  • Key players: QIAGEN N.V., Revvity, and Quest Diagnostics

Market Growth

The North America latent tuberculosis infection detection market size was estimated at USD 553.5 million in 2025 and is predicted to increase from USD 591.14 million in 2026 to approximately USD 1068.64 million by 2035, expanding at a CAGR of 6.8% from 2026 to 2035.

North America Latent Tuberculosis Infection Detection Market Size is USD 591.14 Million in 2026.